Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD5492 phase 1 safety, pharmacokinetics, and pharmacodynamics study in autoimmune diseases
NL-OMON59728Phase 1Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2025
- Modality
- Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of AZD5492 in systemic lupus erythematosus (SLE), Autoimmune Myopathies and rheumatoid arthritis (RA), sponsored by AstraZeneca. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
AZD5492
03
Conditions
systemic lupus erythematosus (SLE)Autoimmune Myopathiesrheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON59728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59728.